Furthermore, post-hoc analysis of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D), presented at the American Diabetes Association 2010 Scientific Sessions, showed that this PPAR-γ agonist could reduce the risk of myocardial infarction in patients with coexisting diabetes and established coronary artery disease [7]. Here, PPARG is linked to diabetes mellitus.